KR100769573B1 - Composition for tablet oral cavity washing agent containing enzymes - Google Patents

Composition for tablet oral cavity washing agent containing enzymes Download PDF

Info

Publication number
KR100769573B1
KR100769573B1 KR1020010039309A KR20010039309A KR100769573B1 KR 100769573 B1 KR100769573 B1 KR 100769573B1 KR 1020010039309 A KR1020010039309 A KR 1020010039309A KR 20010039309 A KR20010039309 A KR 20010039309A KR 100769573 B1 KR100769573 B1 KR 100769573B1
Authority
KR
South Korea
Prior art keywords
tablet
weight
plaque
enzyme
composition
Prior art date
Application number
KR1020010039309A
Other languages
Korean (ko)
Other versions
KR20030003477A (en
Inventor
김후덕
김영호
강택균
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to KR1020010039309A priority Critical patent/KR100769573B1/en
Publication of KR20030003477A publication Critical patent/KR20030003477A/en
Application granted granted Critical
Publication of KR100769573B1 publication Critical patent/KR100769573B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216Solid or semisolid forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 효소를 포함하는 정제형 구강세정제 조성물에 관한 것으로, 글루코스옥시다아제(glucose oxidase), 덱스트라나아제(dextranase), 락토퍼옥시다아제(lactoperoxidase), 글루카나아제(gluconase), 라이소자임(lysozyme), 프로테아제(protease)로 이루어진 군으로부터 1종 이상 선택되는 효소를 포함하는 정제형 구강세정제 조성물을 제공한다. 본 발명의 정제형 구강세정제는 효소의 활성을 안정적으로 유지시켜 프라그 제거, 구취제거 및 구취발생 억제효과가 우수하고, 사용이 간편할 뿐만 아니라 쉽게 휴대가능하다. The present invention relates to a tablet-type mouthwash composition comprising an enzyme, glucose oxidase, dextranase, lactoperoxidase, lactoperoxidase, gluconase, lysozyme, Provided is a tablet-type mouthwash composition comprising an enzyme selected from the group consisting of proteases. Tablet-type mouthwashes of the present invention to maintain the activity of the enzyme stable and excellent in plaque removal, bad breath removal and bad breath occurrence effect, easy to use and easily portable.

효소, 프라그제거, 구취제거, 정제형 구강세정제 Enzyme, plaque removal, bad breath removal, tablet mouthwash

Description

효소를 포함하는 정제형 구강세정제 조성물{COMPOSITION FOR TABLET ORAL CAVITY WASHING AGENT CONTAINING ENZYMES}Tablet-type mouthwash composition containing enzyme {COMPOSITION FOR TABLET ORAL CAVITY WASHING AGENT CONTAINING ENZYMES}

본 발명은 효소를 포함하는 정제형 구강세정제 조성물에 관한 것으로서, 더욱 상세하게는 프라그제거, 구취제거에 효과가 있는 글루코스옥시다아제, 덱스트라나아제, 락토퍼옥시다아제, 글루카나아제, 리소자임 또는 프로테아제를 포함하는 정제형 구강세정제 조성물에 관한 것이다.The present invention relates to a tablet-type mouthwash composition comprising an enzyme, and more particularly includes glucose oxidase, dextranase, lactoperoxidase, glucanase, lysozyme or protease, which are effective for removing plague and bad breath. It relates to a tablet-type mouthwash composition.

구취는 후천적인 전신질환에 의하여 발생되거나, 타액 중의 단백질, 음식물 찌꺼지 등이 구강내 미생물에 의해 아미노산으로 분해된 후 아미노산이 탈회산 효소나 아미노 효소 등에 의해 분해되면서 악취를 유발하는 물질을 생성하여 발생된다. 또한 마늘이나 고추 등을 섭취하는 경우 이들 물질에 함유되어 있는 황화물에 의해서도 구취가 발생하게 된다.   Bad breath is caused by acquired systemic diseases, or protein or food waste in saliva is decomposed into amino acids by microorganisms in the oral cavity, and then amino acids are decomposed by decalcification or amino enzymes to produce substances that cause odor. do. In addition, when ingesting garlic or red pepper, bad breath is also caused by sulfides contained in these substances.

프라그는 치아의 표면에 부착된 백색 내지는 황갈색의 연한 침착물로서, 많은 구강세균과 세균간 기질로 구성되어 있다. 세균간 기질은 세균이 생산하는 다당, 타액의 당단백, 음식물 잔사, 치은구에서의 삼출액의 단백질 등으로 구성되어 있다. 또한 세균간 기질에는 탈락상피세포도 혼합되어 있는 경우가 많다. 프라그 는 주로 치경부, 인접면, 소와 및 열구의 주부 등 기계적 청소가 불완전한 부분에서 다량으로 형성된다.Plaque is a white or tan brown light deposit attached to the surface of a tooth and consists of many oral bacteria and interbacterial substrates. The interbacterial substrate is composed of polysaccharides produced by bacteria, glycoproteins in saliva, food residues, and proteins in effusions from gingival cells. In addition, decellularized epithelial cells are often mixed in the bacterial intercellular matrix. The plaque is formed in large quantities in incomplete parts of the mechanical cleaning, such as the cervical region, the proximal surface, and the main portion of the bovine and fissure.

프라그의 형성은 먼저 치아의 표면에 타액중의 당단백 성분이 막상으로 부착하고, 여기에 세균이 정착, 증식함으로서 시작된다. 초기의 프라그를 형성하고 있는 세균은 구균이지만, 프라그가 성숙함에 따라 세균은 주로 사상균으로 바뀌게 되고, 사상균이 증식하게 되면 프라그는 급격히 두께가 증가된다. The formation of plaques begins by first attaching glycoprotein components in saliva to the surface of the teeth in a film form, whereby bacteria are settled and multiplied. Bacteria that form early plaques are cocci, but as the plaque matures, the bacteria are mainly converted to filamentous fungi, and as the fungi proliferate, the plaques rapidly increase in thickness.

프라그 속의 세균의 종류는 매우 많은데, 그 중에서 주된 것은 스트렙토코커스(Streptococcus), 나이세리아(Neisseria), 바일로넬라(Veillonella), 푸소박테리움(Fusobacterium), 액티노마이세스(Actinomyces), 노카디아(Nocardia), 렙토트리키아(Leptotrichia), 캑토바실러스(Cactobacillus), 캅노사이토페가(Capnocytophaga) 등이다. There are many types of bacteria in the plague , the main ones of which are S treptococcus , Neisseria , Veillonella , Fusobacterium , Actinomyces , and Noh. Arcadia (Nocardia), Escherichia repto tree (Leptotrichia), Bacillus kaekto (Cactobacillus), such as the Cobb the labor Ito Fe (Capnocytophaga).

최근 특히 프라그 중의 연쇄구군인 스트렙토코커스 무탄스(Streptococcus mutans)가 우식을 일으키는 중요한 세균으로서 관심을 모우고 있는데, 이는 스트렙토코커스 무탄스가 음식물 중의 설탕을 분해하여 산을 생성하고, 다량의 글루칸(glucan)이라는 다당류를 생산하기 때문이다. 글루칸은 물에 잘 녹지 않고, 매우 점착성이 높기 때문에 프라그를 치아의 표면에 부착, 정체시키는 역할을 하고 있는 것으로 추정되고 있다. 또한 글루칸은 스트렙토코커스 무탄스 균을 모아 덩어리(괴)로 만드는 작용을 하여 프라그 형성의 한 원인이 되기도 한다. 프라그는 구강내 청결이 불완전한 경우에 많이 나타나며, 구취, 우식, 및 치주질환의 원인이 된다. Recently, the streptococcus mutans, a group of chains in prag, has attracted attention as an important bacterium that causes caries. Streptococcus mutans breaks down sugar in foods to produce acid, which is called glucan. This is because it produces polysaccharides. Glucan does not dissolve well in water and is very sticky. Therefore, glucan is believed to play a role in attaching and stagling plaque on the surface of teeth. Glucan also collects Streptococcus mutans and forms agglomerates, which can be a cause of plaque formation. Plaque is most common when oral cleanliness is incomplete and causes bad breath, caries, and periodontal disease.                         

구취의 생성, 프라그의 생성을 억제하는 약효성분의 중 효소류가 포함된다. 그러나 효소류의 경우 효능은 우수하나 액상 제형에서는 안정성이 좋지 않아 효능을 실현시키기에 많은 어려움이 있다. Heavy enzymes of the active ingredient which suppress bad breath production and the production of plaque are included. However, in the case of enzymes, the efficacy is excellent, but the stability in liquid formulations is difficult to realize a lot of efficacy.

따라서, 본 발명은 프라그를 제거할 수 있는 정제형 구강세정제 조성물을 제공하는 것을 목적으로 한다. Therefore, an object of the present invention is to provide a tablet-type mouthwash composition which can remove plaque.

또한 본 발명은 효소의 안정성을 유지하여 우수한 구강세정 작용을 나타내는 정제형 구강세정제 조성물을 제공하는 것을 목적으로 한다.In addition, an object of the present invention is to provide a tablet-type mouthwash composition that maintains the stability of the enzyme and exhibits excellent mouthwashing action.

또한 본 발명은 사용이 간편하며 휴대가 간편한 정제형 구강세정제 조성물을 제공하는 것을 목적으로 한다. It is another object of the present invention to provide a tablet-type mouthwash composition which is simple to use and portable.

상기의 목적을 달성하기 위하여 본 발명은 정제형 구강세정제 조성물에 있어서, 글루코스옥시다아제(glucose oxidase), 덱스트라나아제(dextranase), 락토퍼옥시다아제(lactoperoxidase), 글루카나아제(gluconase), 라이소자임(lysozyme), 프로테아제(protease)로 이루어진 군으로부터 1종 이상 선택된 효소를 0.01 내지 50 중량%로 포함하는 정제형 구강세정제 조성물을 제공한다.In order to achieve the above object, the present invention provides a tablet-type mouthwash composition, glucose oxidase, dextranase, lactoperoxidase, lactoperoxidase, gluconase, lysozyme ), Provides a tablet-type mouthwash composition comprising 0.01 to 50% by weight of one or more enzymes selected from the group consisting of protease.

이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.

본 발명의 정제형 구강세정제 조성물은 글루코스옥시다아제(glucose oxidase, GOD), 덱스트라나아제(dextranase), 락토퍼옥시다아네(lactoperoxidase), 글루카나아제(glucanase), 리소자임(lysozyme) 및 프로테아제(protease)로 이루어 진 군으로부터 선택된 1종 이상의 효소를 0.01 중량% 내지 50 중량%로 포함한다. 효소의 함량이 0.01 중량% 미만인 경우 구강내 효소작용에 의한 효과를 기대하기 어렵고, 50 중량% 초과할 경우 과량의 효소사용으로 유익한 구강미생물까지 살균될 위험성이 있다. 가장 바람직하게는 상기 효소를 0.1 ∼ 30 중량%로 포함하는 것이다. Tablet-type mouthwash composition of the present invention is glucose oxidase (GOD), dextranase (dextranase), lactoperoxidase (lactoperoxidase), glucanase, lysozyme and protease (protease) 0.01 wt% to 50 wt% of one or more enzymes selected from the group consisting of If the content of the enzyme is less than 0.01% by weight it is difficult to expect the effect by the oral enzymatic action, if the amount exceeds 50% by weight there is a risk of sterilization to the beneficial oral microorganisms by the use of excess enzyme. Most preferably, the enzyme is contained in an amount of 0.1 to 30% by weight.

상기 글루코스옥시다아제는 구강 내 미생물을 이용함으로써 프라그를 생성시키는 글루코스를 분해하여 프라그 생성을 억제시키고, 과산화수소를 생성시켜 살균작용을 유도한다. 덱스트라나아제는 덱스트란의 1, 6-[α]-글루코시드 연결(glucosidic linkages)를 분해하며 구강내 생성된 덱스트란을 분해하여 프라그의 생성을 억제하고, 락토퍼옥시다아제는 구강내 락토스(유당)을 분해하고 과산화수소를 생성하여 살균작용을 한다. 글루카나아제는 스트렙토코커스 무탄스에 의해 생성된 글루칸을 분해하여 프라그가 치아에 점착되는 것을 억제한다. 라이소자임과 프로테아제는 구강내 서식하는 미생물 세포벽에 작용하여 구취 및 프라그 생성 원인균의 생육을 억제한다.The glucose oxidase inhibits plaque production by decomposing glucose producing plaque by using microorganisms in the oral cavity, and induces bactericidal action by generating hydrogen peroxide. Dextranase decomposes 1, 6- [α] -glucosidic linkages of dextran and decomposes dextran produced in the oral cavity to inhibit the production of plaque, and lactoperoxidase is used in oral lactose ( Lactose) disintegrates and produces hydrogen peroxide to sterilize. Glucanase breaks down the glucan produced by Streptococcus mutans and inhibits plaque from sticking to the teeth. Lysozyme and protease act on the microbial cell walls that live in the oral cavity and inhibit the growth of bad bacteria and plaque-producing bacteria.

또한 본 발명의 정제형 구강세정제 조성물은 발포제 1 내지 55 중량%, 습기제거제 0.1 내지 20 중량%, pH 조정제 0.1 내지 5 중량%, 기포제 1 내지 5 중량%, 결합제 0.1 내지 10 중량%, 활택제는 처방에 따라 사용하지 않아도 무방하며 사용시에는 0.05 내지 3 중량%, 향미제 0.1 내지 15 중량%, 용매는 처방에 따라 사용하지 않아도 무방하며 사용시에는 0.1 내지 15 중량%, 및 약효제 0.001 내지 10 중량%를 포함할 수 있다. In addition, the tablet mouthwash composition of the present invention is 1 to 55% by weight of the blowing agent, 0.1 to 20% by weight of the dehumidifying agent, 0.1 to 5% by weight of the pH adjuster, 1 to 5% by weight of the foaming agent, 0.1 to 10% by weight of the binder, the lubricant It is not necessary to use it according to the prescription, and when used, 0.05 to 3% by weight, the flavoring agent 0.1 to 15% by weight, the solvent may not be used according to the prescription, and when used, 0.1 to 15% by weight, and 0.001 to 10% by weight of the drug It may include.                     

상기 발포제는 탄산수소나트륨, 탄산수소암모늄, 탄산수소칼륨 및 탄산철로 이루어진 군에서 1종 이상 선택되는 것이 바람직하고, 구강내 세균에 대한 억제효과가 우수하며, 프라그에 의해 생성되는 유기산을 중화시킴으로써 충치예방 효과와 부드러운 연마력을 갖고 있는 탄산수소나트륨이 가장 바람직하다.The blowing agent is preferably at least one selected from the group consisting of sodium bicarbonate, ammonium bicarbonate, potassium bicarbonate and iron carbonate, has an excellent inhibitory effect on oral bacteria, and decays by neutralizing organic acids produced by plaque. Sodium bicarbonate, which has a prophylactic effect and a soft polishing power, is most preferred.

상기 습기제거제는 탄산나트륨이 바람직하고, 상기 pH 조정제는 구연산 또는 구연산 나트륨이 바람직하다. 상기 결합제의 용해에 사용되는 용매는 폴리프로필렌 글리콜, 글리세린 또는 에탄올이 바람직하다.The dehumidifying agent is preferably sodium carbonate, and the pH adjuster is preferably citric acid or sodium citrate. The solvent used for dissolving the binder is preferably polypropylene glycol, glycerin or ethanol.

상기 기포제는 사용감을 증진시키고, 세정작용을 도와주며 기타 약효성분의 분산 및 침투를 신속하게 하고 계면장력을 감소시킴으로써 구강내 이물질을 쉽게 떨어지는 작용을 한다. 기포제는 주로 음이온성 계면활성제인 라우릴황산나트륨이 바람직하며, 제형의 특성에 따라 비이온성 계면활성제인 폴리옥시에틸렌폴리옥시프로필렌의 공중합체(폴로사머), 폴리옥시에틸렌경화파마자유, 폴리옥시에틸렌솔비탄 지방산에스테르 등이 사용될 수 있다. The foaming agent acts to drop foreign substances in the oral cavity by enhancing the feeling of use, helping to cleanse, and rapidly dispersing and penetrating other drug substances and reducing interfacial tension. The foaming agent is preferably an anionic surfactant, sodium lauryl sulfate, and a copolymer of a nonionic surfactant polyoxyethylene polyoxypropylene (polosomer), polyoxyethylene cured oil, and polyoxyethylene sorbbi depending on the characteristics of the formulation. Carbon fatty acid esters and the like can be used.

상기 결합제는 수용성의 고분자가 바람직하며 더욱 바람직하게는 카복실메틸 셀룰로즈 또는 폴리비닐피롤리돈이고, 활택제는 스테아린산마그네슘, 스테아린산, 스테아릴알콜, 자당지방산에스테르, 탈크, 경질무수규산 또는 안식향산 나트륨이다. 또한 향미제로는 사카린 나트륨, 사카린, 글리틸리틴 등이 있고, 향료로서는 레몬, 오렌지, 파인, 민트, 멘톨 등이 있으며, 충치 예방기능의 치석제거제로서 뿐만 아니라 치아조직을 강화시켜주는 기능을 갖도록 하기 위하여 불화나트륨 또는 불소계화합물을 약효제로 포함한다. 또한 본 발명의 구강세정제 조성물은 착색제 를 더욱 포함할 수 있다. 착색제로는 황색삼이산화철, 적색삼이산화철, 타르계 색소 등이 있다. The binder is preferably a water-soluble polymer, more preferably carboxymethyl cellulose or polyvinylpyrrolidone, and the lubricant is magnesium stearate, stearic acid, stearyl alcohol, sucrose fatty acid ester, talc, hard silicic anhydride or sodium benzoate. In addition, flavoring agents include sodium saccharin, saccharin, and glycyritin, and lemons, oranges, pines, mints, menthols, and the like. Sodium fluoride or fluorine-containing compound is included as a medicament. In addition, the mouthwash composition of the present invention may further include a colorant. As a coloring agent, yellow triiron dioxide, red trioxide, tar type pigment | dye, etc. are mentioned.

본 발명의 정제형 구강세정제는 통상의 정제형 구강세정제의 제조방법으로 실시될 수 있으며, 바람직하게는 상기 발포제, 습기제거제, pH 조정제를 혼합하고, 용매에 녹인 결합제 용액과 더욱 혼합한 다음 과립상으로 제조하여 건조시킨 후 정립하여 효소, 활택제, 기포제, 약효제와 혼합하여 정제를 제조한다. 본 발명의 정제형 구강세정제는 정제의 형상으로, 원형 정제 또는 보통 R면, 당의 R면, 스미커크평면, 스미말평면, 2단R면 등의면형을 가지는 각종 이형정으로 제조될 수 있으며, 1정이 0.01 내지 5 g인 것이 바람직하고, 가장 바람직하게는 1.0 + 0.1g이다. 상기 1정을 1 ml-2000 ml의 음용수에 녹여 30초간 가글함으로써 구강세정할 수 있다. The tablet mouthwash of the present invention may be carried out by a conventional method for preparing a tablet mouthwash, and preferably, the blowing agent, the moisture remover, and the pH adjuster are mixed, further mixed with a binder solution dissolved in a solvent, and then granular. It is prepared by drying, sizing, sizing and mixing with enzymes, lubricants, foaming agents, and medicaments to produce tablets. Tablet-type mouthwashes of the present invention in the form of tablets, can be prepared in a variety of release tablets having a circular tablet or a surface shape such as ordinary R surface, sugar R surface, Smeker plane, smear plane, two-stage R surface, 1 It is preferable that the tablets are 0.01-5 g, Most preferably, it is 1.0 + 0.1 g. The tablets can be washed orally by dissolving in 1 ml-2000 ml of drinking water and gargle for 30 seconds.

본 발명의 정제형 구강세정제 조성물은 무수물로 이루어져 있어, 효소의 안정성이 높아 효소의 본래의 기능을 유지시키고, 사용시 종래의 액상 제형보다 우수한 효과를 얻을 수 있었다. 또한 정제형 구강세정제 조성물은 사용자가 사용 직전 물에 녹여 사용할 수 있으므로, 사용장소에 구애를 받지 않고 휴대가 간편한 장점을 가지고 있다. The tablet-type mouthwash composition of the present invention is composed of anhydride, high stability of the enzyme to maintain the original function of the enzyme, it was able to obtain a superior effect than the conventional liquid formulation when used. In addition, since the tablet-type mouthwash composition can be used by the user dissolved in water immediately before use, regardless of the place of use has the advantage of easy to carry.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐 본 발명이 하기의 실시예에 한정되는 것은 아니다.     Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are provided only to more easily understand the present invention, and the present invention is not limited to the following examples.

[실시예]  EXAMPLE                     

표 1에 나타난 성분 및 함량으로 실시예 1 내지 5의 구강세정 정제를 제조하였다. 제조방법은 먼저, 발포제, 습기제거제, pH 조정제를 혼합하고, 용매에 결합제를 녹여 상기 혼합물에 투입하여 교반하였다. 교반 후 과립기를 이용하여 일정한 크기로 과립을 제조하고 건조시켰다. 건조된 과립을 정립한 후 혼합하고, 효소분말, 기포제, 활택제, 약효제를 혼합하여 건조된 과립과 교반한 다음 1.0 + 0.1 g의 정제를 제조하였다. The mouthwash tablets of Examples 1 to 5 were prepared using the ingredients and contents shown in Table 1. In the manufacturing method, first, a blowing agent, a dehumidifying agent and a pH adjuster were mixed, the binder was dissolved in a solvent, and the mixture was added and stirred. After stirring, granules were prepared to a constant size using a granulator and dried. After the granules were dried and mixed, enzyme powder, foaming agent, lubricant, and agonist were mixed and stirred with the dried granules to prepare 1.0 + 0.1 g of tablet.

원료구분Raw material classification 원료명Raw material name 비교예Comparative example 실시예1Example 1 실시예2Example 2 실시예3Example 3 실시예4Example 4 실시예5Example 5 효소enzyme 글루코스옥시다아제Glucose oxidase -- 20.020.0 -- -- -- -- 덱스트라나아제Dextranase -- -- 2.02.0 -- 12.012.0 15.015.0 락토퍼옥시다아제Lactoperoxidase -- -- -- 5.05.0 -- -- 글루카나아제Glucanase -- -- -- 25.025.0 5.05.0 -- 라이소자임Lysozyme -- -- 10.010.0 -- 7.07.0 15.015.0 프로테아제Protease -- 9.09.0 -- -- 5.05.0 -- 발포제blowing agent 탄산수소나트륨Sodium bicarbonate -- 38.038.0 35.035.0 36.036.0 37.037.0 3535 습기제거제Dehumidifier 탄산나트륨Sodium carbonate -- 8.08.0 10.010.0 9.09.0 9.09.0 9.09.0 pH 조정제pH regulator 구연산Citric acid 0.010.01 0.50.5 0.50.5 0.50.5 0.50.5 0.50.5 구연산 나트륨Sodium citrate 0.20.2 1.51.5 1.51.5 1.51.5 1.51.5 2.02.0 기포제Foam 라우릴황산 나트륨Sodium lauryl sulfate 0.40.4 3.03.0 3.03.0 3.03.0 3.03.0 3.03.0 결합제Binder 카복실메틸 셀루로즈Carboxylmethyl Cellulose -- 3.03.0 1.01.0 -- 2.02.0 2.52.5 폴리비닐피롤리돈Polyvinylpyrrolidone -- -- 2.02.0 3.03.0 1.01.0 -- 활택제Lubricant 안식향산 나트륨Sodium benzoate -- 1.01.0 1.01.0 1.01.0 1.01.0 1.01.0 향미제Flavor 사카린 나트륨Saccharin Sodium 0.010.01 1.01.0 1.01.0 1.01.0 1.01.0 1.01.0 incense 0.150.15 5.05.0 5.05.0 5.05.0 5.05.0 6.06.0 용매menstruum 폴리프로필렌 글리콜Polypropylene glycol -- 5.05.0 5.05.0 -- -- -- 글리세린glycerin 12.012.0 -- -- 6.06.0 6.06.0 6.06.0 에탄올ethanol 8.08.0 3.03.0 3.03.0 2.02.0 2.02.0 2.02.0 정제수Purified water 79.2179.21 -- -- -- -- -- 불화나트륨Sodium fluoride 0.020.02 2.02.0 2.02.0 2.02.0 2.02.0 2.02.0 약효제Medicinal agents 합계Sum 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0

[비교예][Comparative Example]

상기 표 1의 비교예 조성물로 정제를 제조하였다. Tablets were prepared by the Comparative Example composition of Table 1.                     

[실험예]Experimental Example

(1) 미생물살균력평가(1) Microbial Sterilization Evaluation

실시예 1 내지 실시예 5의 정제들에 의해 발생된 과산화물에 의한 구취발생균에 살균 효과 및 미생물 생육억제효과를 확인하였다. The bactericidal effect and the microbial growth inhibitory effect on the bad breath causing bacteria caused by the peroxide generated by the tablets of Examples 1 to 5 were confirmed.

THB(Todd Hewitt Broth) 복합배지 3 % 용액 10 ml에 스트렙토코커스 무탄스를 접종하여 12시간 배양하였다. 상기 배양액 5 ml을 THB 복합배지 500 ml에 접종하고 다시 12시간 배양하였고, 2차 배양액 200 ml에 실시예 1 내지 실시예 5 또는 비교예의 정제 1정을 각각 투여하고, 투여 1분, 5분, 15분, 30분 후에 백금봉으로 상기 배양액을 아가플레이트에 스트리킹하여 하룻밤 배양하고, 미생물의 성장 여부를 육안으로 확인하였다. Streptococcus mutans was inoculated in 10 ml of THB (Todd Hewitt Broth) complex 3% solution and incubated for 12 hours. 5 ml of the culture solution was inoculated into 500 ml of THB complex medium and incubated for another 12 hours. One tablet of Example 1 to Example 5 or Comparative Example was administered to 200 ml of the secondary culture solution, respectively, for 1 minute, 5 minutes, After 15 minutes and 30 minutes, the culture solution was streaked on an agar plate with a platinum rod and cultured overnight, and the growth of microorganisms was visually confirmed.

그 결과, 실시예 1 내지 실시예 5의 정제는 배양액에 투여한 후 1분, 5분, 15분, 30분 후에 아가플레이트에서 미생물의 증식을 확인하였으나, 미생물의 성장이 전혀 없음을 확인할 수 있었다. 반면 비교예의 정제의 경우 미생물이 성장한 것을 확인할 수 있어, 실시예 1 내지 실시예 5의 정제가 미생물 살균효과가 뛰어남을 알 수 있었다. As a result, the tablets of Examples 1 to 5 confirmed the growth of the microorganisms in the agar plate after 1 minute, 5 minutes, 15 minutes, and 30 minutes after administration to the culture medium, but it was confirmed that there was no growth of the microorganisms. . On the other hand, in the case of the tablets of the comparative example, it was confirmed that the microorganisms were grown, and the tablets of Examples 1 to 5 were found to have excellent microbial sterilization effect.

(2) 프라그 생성억제효과(2) plaque generation inhibitory effect

프라그의 발생을 치태지수(Plaque Index, Turesky Quigley and Hein ) 방법으로 평가하였다.The incidence of plaques was assessed by the Plaque Index, Turesky Quigley and Hein method.

비교적 치열이 고르고 치아우식증이 없는 성인남녀 21세 내지 35세의 36명을 실험대상자로 선정하고, 고른 등급을 갖는 각 6명씩 6그룹으로 나누었다. 동일 조 건을 만들기 위해 6그룹 모든 대상자에게 표준 치약과 칫솔을 제공하여 1주간 사용하게 하였다. 이때 치약, 칫솔은 1일 3회 사용하게 하고 치약, 칫솔을 제외한 구강위생제품의 사용은 중단시켰다. 표준 치약과 칫솔을 일일 3회 사용하면서 실시예 1 내지 실시예 5의 정제로 매일 5회 30초 이상 가글을 하도록 하여 4주간 사용하게 하였다. 4주 후 모든 실험대상자의 치아에 부착된 프라그를 덴탈 디스클로징 용액(Dental Disclosing Solution)으로 착색하여 개개인 치아의 협순면 및 설면의 프라그를 아래의 기준으로 평점하였고, 치태지수를 하기 표 2에 기재하였다. Thirty-six adult women aged between 21 and 35 years of age with relatively even dentition and no dental caries were selected as subjects and divided into six groups of six individuals with even grades. To create the same condition, all subjects in Group 6 were provided with standard toothpaste and toothbrushes for one week. At this time, toothpaste and toothbrushes were used three times a day and the use of oral hygiene products except toothpaste and toothbrushes were discontinued. The standard toothpaste and toothbrush were used three times a day, and the tablets of Examples 1 to 5 were allowed to goggle five times daily for 30 seconds or more for four weeks. Four weeks later, the plaques attached to the teeth of all subjects were stained with a dental disclosing solution, and the plaques of the buccal and lingual surfaces of the individual teeth were evaluated based on the following criteria, and the plaque indexes are shown in Table 2 below. It was.

평점기준Rating criteria

0 점: 치면 세균막이 없는 경우0 points: If there is no biofilm

1점 : 치은연부에 점상으로 치면 세균막이 있는 경우1 point: If there is a bacterial film on the gingival edge

2점: 치은연에 따라서 분명한 선상으로 치면 세균막이 있는 경우2 points | pieces: When there is a bacterial film | membrane when it is lined clearly along the gingival margin

3점: 치경부측 1/3 이하 치면에 치면 세균막이 있는 경우3 points | pieces: When there is a bacterial film on the tooth surface below 1/3 of the cervical side

4점: 치경부측 1/3이상 2/3이하 치면에 치면 세균막이 있는 경우4 points: If there is a bacterial film on the tooth surface 1/3 to 2/3 or less

5점: 치경부측 2/3이상 치면에 치면 세균막이 있는 경우
5 points | pieces: When there is a bacterial film on the tooth surface more than 2/3 of the cervical side

비교예Comparative example 실시예1Example 1 실시예2Example 2 실시예3Example 3 실시예4Example 4 실시예5Example 5 전치아Pre-teeth baselinebaseline 2.52+0.392.52 + 0.39 2.54+0.282.54 + 0.28 2.52+0.282.52 + 0.28 2.5+0.202.5 + 0.20 2.49+0.252.49 + 0.25 2.52+0.332.52 + 0.33 4주4 Weeks 2.43+0.322.43 + 0.32 2.30+0.212.30 + 0.21 2.27+0.282.27 + 0.28 2.22+0.292.22 + 0.29 2.16+0.272.16 + 0.27 2.23+0.392.23 + 0.39 감소율(%)% Reduction 3.573.57 9.289.28 10.0510.05 11.4811.48 13.0313.03 11.5811.58 앞니incisor baselinebaseline 2.47+0.382.47 + 0.38 2.49+0.312.49 + 0.31 2.52+0.302.52 + 0.30 2.48+0.492.48 + 0.49 2.50+0.192.50 + 0.19 2.53+0.342.53 + 0.34 4주4 Weeks 2.27+0.372.27 + 0.37 2.23+0.292.23 + 0.29 2.12+0.222.12 + 0.22 2.14+0.382.14 + 0.38 2.10+0.262.10 + 0.26 2.15+0.272.15 + 0.27 감소율(%)% Reduction 8.098.09 10.3610.36 15.9615.96 13.8213.82 15.9915.99 15.0515.05 어금니molar baselinebaseline 2.54+0.512.54 + 0.51 2.56+0.422.56 + 0.42 2.57+0.252.57 + 0.25 2.57+0.362.57 + 0.36 2.58+0.412.58 + 0.41 2.54+0.442.54 + 0.44 4주4 Weeks 2.55+0.322.55 + 0.32 2.39+0.442.39 + 0.44 2.41+0.532.41 + 0.53 2.39+0.442.39 + 0.44 0.28+0.300.28 + 0.30 2.35+0.452.35 + 0.45 감소율(%)% Reduction 0.030.03 6.666.66 6.186.18 6.996.99 7.737.73 7.567.56 치간면Interdental baselinebaseline 2.48+0.492.48 + 0.49 2.38+0.502.38 + 0.50 2.41+0.212.41 + 0.21 2.45+0.202.45 + 0.20 2.42+0.302.42 + 0.30 2.43+0.182.43 + 0.18 4주4 Weeks 2.26+0.422.26 + 0.42 2.12+0.412.12 + 0.41 2.02+0.372.02 + 0.37 2.11+0.362.11 + 0.36 2.02+0.402.02 + 0.40 2.04+0.242.04 + 0.24 감소율(%)% Reduction 8.878.87 11.0911.09 15.9915.99 13.8913.89 16.4716.47 16.0816.08

표 2에 나타난 바와 같이, 초기에는 비교예와 실시예 1 내지 5의 정제 실험군간에 통계적인 유의성이 없었다(p<0.05). 4주 후 비교예를 실시한 실험군은 앞니와 치간면에 프라그가 감소되었고, 실시예 1 내지 5를 실시한 실험군 등은 전치아, 앞니, 치간면에서 프라그 지수가 총계적으로 유의성 있게 감소하였으며(p<0.05), 어금니에서도 통계적으로 유의성 있게 프라그 지수가 감소하였다. 따라서, 실시예 1 내지 5의 정제가 프라그의 생성을 억제시킴을 알 수 있었고, 특히 실시예 2 및 실시예 4의 정제가 더욱 효과적이었다. As shown in Table 2, initially, there was no statistical significance between the comparative examples and the purification experiment groups of Examples 1 to 5 (p <0.05). Four weeks later, the experimental group of the comparative example had a decrease in plaque on the incisors and the interdental surface, and the experimental groups of Examples 1 to 5 significantly reduced the plaque index on the front teeth, the incisors, and the interdental surface (p < 0.05), the plaque index decreased significantly in molars. Thus, it was found that the tablets of Examples 1 to 5 inhibited the production of plaque, and in particular, the tablets of Examples 2 and 4 were more effective.

(3) 구취제거효과(3) bad breath removal effect

치아 우식을 가지고 있지 않은 남녀 36명을 선정하여 대상 음료에 대하여 교차 반복 실험(Cross-over test)을 실시하였다. 시판하는 마늘분을 물에 분산시켜 24시간 방치한 후 희석하여 할리미터(Halimeter)측정값이 700 ppb 이상이 되도록 하였으며, 상기 희석액을 구취 유발원으로 사용하였다. 마늘분 희석액 15 ml로 30초간 가글을 한 후 1분 뒤에 할리미터로 구취정도를 측정하였으며, 다시 각각의 비교예의 정제, 실시예 1 내지 5의 정제를 15 ml에 녹여 30초간 가글을 하였다. 가글 후 30초, 5분, 30분 경과한 다음 할리미터로 구취정도를 측정하여 구취억제의 지속 여부를 확인하였다. 하기 표 3은 본 발명의 구강세척 정제로 가글한 후 구취억제정도를 확인한 것이다. 36 men and women who did not have dental caries were selected and subjected to a cross-over test. Commercial garlic powder was dispersed in water, left to stand for 24 hours, and diluted to make a Halimeter measurement value of 700 ppb or more. The diluted solution was used as a bad breath source. Garlic was diluted with 15 ml of garlic powder for 30 seconds, and after 1 minute, the degree of bad breath was measured with a halimeter. Then, the tablets of Comparative Examples and Examples 1 to 5 were dissolved in 15 ml and gargled for 30 seconds. After 30 seconds, 5 minutes, and 30 minutes after goggle, the degree of bad breath was measured by using a halimeter to determine whether or not to suppress bad breath. Table 3 below confirms the degree of bad breath inhibition after gargled with the oral wash tablet of the present invention.

구분division 가글후 경과시간Elapsed time after gargle 30 초30 sec 5 분5 minutes 30 분30 minutes 비교예Comparative example 55.7 %55.7% 45.5 %45.5% -5.9 %-5.9% 실시예1Example 1 74.5 %74.5% 73.2 %73.2% 67.0 %67.0% 실시예2Example 2 78.3 %78.3% 74.6 %74.6% 70.4 %70.4% 실시예3Example 3 86.2 %86.2% 83.5 %83.5% 75.3 %75.3% 실시예4Example 4 88.6 %88.6% 84.0 %84.0% 74.2 %74.2% 실시예5Example 5 81.3 %81.3% 78.9 %78.9% 71.0 %71.0%

표 3에 나타난 바와 같이, 비교예의 정제는 가글 후 5분까지 구취억제의 지속성이 약간 나타났으나 가글 후 30분 뒤에는 오히려 구취정도가 증가함을 보여 구취 억제 지속성이 거의 없음을 알 수 있었다. 반면, 실시예 1 내지 실시예 5의 정제는 구위억제 지속성이 있음을 확인하였다. As shown in Table 3, the tablets of the comparative example showed a slight persistence of bad breath suppression until 5 minutes after gargle, but showed an increase in the degree of bad breath after 30 minutes after gargle. On the other hand, it was confirmed that the tablets of Examples 1 to 5 have persistent persistence.

본 발명의 정제형 구강세정제 조성물은 효소의 활성을 안정적으로 유지시켜 프라그 제거, 구취제거 및 구취발생억제효과가 우수하며, 정제형으로 제조되므로 사용이 간편하고 휴대가 용이하다. The tablet-type mouthwash composition of the present invention maintains the activity of the enzyme stably, excellent in plaque removal, bad breath removal and bad breath occurrence inhibitory effect, because it is manufactured in a tablet form, it is easy to use and easy to carry.

Claims (2)

정제형 구강세정제 조성물에 있어서, 글루코스옥시다아제(glucose oxidase), 덱스트라나아제(dextranase), 락토퍼옥시다아제(lactoperoxidase), 글루카나아제(gluconase), 라이소자임(lysozyme), 프로테아제(protease)로 이루어진 군으로부터 1종 이상 선택된 효소 0.01 내지 50 중량% 및 습기제거제 0.1 내지 9 중량%를 포함하는 정제형 구강세정제 조성물.In the tablet-type mouthwash composition, from the group consisting of glucose oxidase, dextranase, lactoperoxidase, gluconase, lysozyme, protease Tablet type mouthwash composition comprising 0.01 to 50% by weight of one or more selected enzymes and 0.1 to 9% by weight of a dehumidifying agent. 제 1항에 있어서, 상기 구강세정제 조성물은 글루코스옥시다아제(glucose oxidase), 덱스트라나아제(dextranase), 락토퍼옥시다아제(lactoperoxidase), 글루카나아제(gluconase), 라이소자임(lysozyme), 프로테아제(protease)로 이루어진 군으로부터 1종 이상 선택된 효소 0.01 내지 50 중량%, 습기제거제 0.1 내지 9 중량%, 발포제 1 내지 55 중량%, pH 조정제 0.1 내지 5 중량%, 기포제 1 내지 5 중량%, 결합제 0.1 내지 10 중량%, 활택제 0.05 내지 3 중량%, 향미제 0.1 내지 15 중량%, 용매 0.1 내지 15 중량%, 및 약효제 0.001 내지 10 중량%를 포함하는 것을 특징으로 하는 구강세정제 조성물.According to claim 1, wherein the mouthwash composition is a glucose oxidase (dextrinase), dextranase (lactranperase), lactoperoxidase (lactoperoxidase), gluconase (gluconase), lysozyme, protease (protease) 0.01 to 50% by weight of at least one enzyme selected from the group consisting of, 0.1 to 9% by weight of the dehumidifying agent, 1 to 55% by weight of the blowing agent, 0.1 to 5% by weight of the pH adjuster, 1 to 5% by weight of the foaming agent, 0.1 to 10% by weight of the binder , 0.05-3% by weight of lubricant, 0.1-15% by weight of flavor, 0.1-15% by weight of solvent, and 0.001-10% by weight of agonist.
KR1020010039309A 2001-07-02 2001-07-02 Composition for tablet oral cavity washing agent containing enzymes KR100769573B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020010039309A KR100769573B1 (en) 2001-07-02 2001-07-02 Composition for tablet oral cavity washing agent containing enzymes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020010039309A KR100769573B1 (en) 2001-07-02 2001-07-02 Composition for tablet oral cavity washing agent containing enzymes

Publications (2)

Publication Number Publication Date
KR20030003477A KR20030003477A (en) 2003-01-10
KR100769573B1 true KR100769573B1 (en) 2007-10-23

Family

ID=27713052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020010039309A KR100769573B1 (en) 2001-07-02 2001-07-02 Composition for tablet oral cavity washing agent containing enzymes

Country Status (1)

Country Link
KR (1) KR100769573B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200074536A (en) 2018-12-17 2020-06-25 진태원 Abrasive-free foamable solid mouthwash
KR102666564B1 (en) 2023-05-25 2024-05-23 강운철 Mouthwash composition with excellent effect of improving gum disease by containing topan salt

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5809775B2 (en) * 2008-02-14 2015-11-11 株式会社ロッテ Effervescent solid preparation for oral cleaning
EP3192495A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192498A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192494A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192496B1 (en) * 2016-01-12 2022-08-24 Unilever IP Holdings B.V. Oral care compositions
CN112190499B (en) * 2020-11-12 2022-03-01 好易康生物科技(广州)有限公司 Lysozyme oral care product for whitening teeth
CN115813799A (en) * 2022-12-09 2023-03-21 云南白药集团健康产品有限公司 Whitening and tooth-protecting composition and application thereof in oral care products

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02250816A (en) * 1989-03-23 1990-10-08 Kao Corp Composition for oral cavity application
KR950016698A (en) * 1993-12-29 1995-07-20 최근선 Foamable Density Cleaner Composition
JPH07187977A (en) * 1993-12-24 1995-07-25 Lion Corp Composition for oral cavity
KR19980013946A (en) * 1996-08-05 1998-05-15 성재갑 Oral composition of liquid type

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02250816A (en) * 1989-03-23 1990-10-08 Kao Corp Composition for oral cavity application
JPH07187977A (en) * 1993-12-24 1995-07-25 Lion Corp Composition for oral cavity
KR950016698A (en) * 1993-12-29 1995-07-20 최근선 Foamable Density Cleaner Composition
KR19980013946A (en) * 1996-08-05 1998-05-15 성재갑 Oral composition of liquid type

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200074536A (en) 2018-12-17 2020-06-25 진태원 Abrasive-free foamable solid mouthwash
KR102666564B1 (en) 2023-05-25 2024-05-23 강운철 Mouthwash composition with excellent effect of improving gum disease by containing topan salt

Also Published As

Publication number Publication date
KR20030003477A (en) 2003-01-10

Similar Documents

Publication Publication Date Title
KR100294515B1 (en) Effervescent tablet for oral cleaning and preparation method thereof
US5104644A (en) Mouthrinse composition
RU2333768C2 (en) Ferment-containing composition of improved stability for oral cavity
RU2355420C2 (en) Toothpaste containing lactulose, betaine, chondroitin sulphate and enzymes: papain, lysocim, ribonuclease and lidase
RU2289392C2 (en) Antibacterial agent for teeth cleaning, removing of dental plaque and respiratory refreshing
CA2146330C (en) Antibacterial mouthwash
RU2287322C2 (en) Antibacterial preparation for cleaning teeth of improved properties against dental covering and for refreshed breathing
RU2381021C2 (en) Liposome containing tooth paste
WO1992005766A1 (en) Agents effecting the lysis of oral bacteria
KR100769573B1 (en) Composition for tablet oral cavity washing agent containing enzymes
KR102090119B1 (en) Toothpaste composition comprising herbal extract mixture as effective component
RU2496468C2 (en) Tooth paste containing mixed bacterial lysate
MX2007007201A (en) Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces.
US20110318283A1 (en) Use of antibacterial compounds for the oral cavity hygiene
JP2011126819A (en) Composition for oral cavity
JP3783762B2 (en) Stain removal oral composition
KR20030089047A (en) Composition for enhancing oral health
Pader Dental products
RU2496469C2 (en) Nonabrasive tooth paste containing enzyme papain, sphagnum extract, polymethylvinyl alcohol - maleic acid copolymer sodium-calcium salt, n-cocoyl ethyl arginate d,l-pyrrolidone carboxylate and sodium fluoride
CN109260033B (en) Solid gargle granule and preparation method thereof
KR100963301B1 (en) Toothpaste composition comprising hemp fiber
CA1126160A (en) Pure alkali metal salts of lauryl (dodecyl) sulphate in oral composition
KR100665891B1 (en) Oral hygiene compositions containing hydroxytyrosol
KR101963215B1 (en) Oral cleansing composition containing rice bran, rice straw, hog millet
KR20170103482A (en) Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20120914

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20130913

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140917

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20150917

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20160919

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20170928

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20180927

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20191014

Year of fee payment: 13